Enhancing Mitochondrial Health to Treat Hypertension
Purpose of Review
This review summarizes literature pertaining to the dawning field of therapeutic targeting of mitochondria in hypertension and discusses the potential of these interventions to ameliorate hypertension-induced organ damage.
In recent years, mitochondrial dysfunction has been reported as an important contributor to the pathogenesis of hypertension-related renal, cardiac, and vascular disease. This in turn prompted development of novel mitochondria-targeted compounds, some of which have shown promising efficacy in experimental studies and safety in clinical trials. In addition, drugs that do not directly target mitochondria have shown remarkable benefits in preserving these organelles in experimental hypertension.
Enhancing mitochondrial health is emerging as a novel feasible approach to treat hypertension. Future perspectives include mechanistic experimental studies to establish a cause-effect relationship between mitochondrial dysfunction and hypertension and further clinical trials to confirm the reno-, cardio-, and vasculo-protective properties of these compounds in hypertension.
KeywordsBlood pressure Hypertension Mitochondria Heart Kidney Vasculature
This study was partly supported by NIH grant numbers DK104273, HL123160, DK100081, DK102325, and DK106427.
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 11.Eirin A, Ebrahimi B, Kwon SH, Fiala JA, Williams BJ, Woollard JR, et al. Restoration of mitochondrial cardiolipin attenuates cardiac damage in swine renovascular hypertension. J Am Heart Assoc. 2016;5(6)Google Scholar
- 28.•• Saad A, Herrmann SMS, Eirin A, Ferguson CM, Glockner JF, Bjarnason H, et al. Phase 2a clinical trial of mitochondrial protection (elamipretide) during stent revascularization in patients with atherosclerotic renal artery stenosis. Circ Cardiovasc Interv. 2017;10(9) This pilot study showed that adjunctive mitoprotection during renal revascularization attenuates post-procedural hypoxia and improved kidney function in human renovascular hypertension. PubMedGoogle Scholar
- 37.•• Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, et al. Dominiczak AF: Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009;54(2):322–8. This article reported that treatment with mitochondria-targeted antioxidants protected against the development of hypertension and reduced cardiac hypertrophy in hypertensive rats. CrossRefGoogle Scholar
- 71.•• McLachlan J, Beattie E, Murphy MP, Koh-Tan CH, Olson E, Beattie W, et al. Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function. J Hypertens. 2014;32(3):555–64. This article revealed that combining antihypertensives and mitochondria-targeted peptides has additional therapeutic benefit for attenuating hypertension-induced myocardial damage. CrossRefGoogle Scholar